Ascletis Reported Positive Psoriasis Drug Results
A clinical trial showed that the experimental oral drug ASC50 significantly reduced plaque psoriasis symptoms.
Updated on Sept. 29, 2026 in Diseases — General
Live Poll
Would you prefer an oral medication over injectable treatments if you had a chronic skin condition?
Ascletis Pharma has completed a 28-day clinical trial for its plaque psoriasis treatment, ASC50. The study reported a 48.9 percent placebo-adjusted reduction in PASI scores among participants.
Why it matters
The study successfully demonstrated that ASC50 could provide an effective, once-weekly oral alternative to currently available injectable antibody therapies for psoriasis patients.
The study utilized a 200 mg once-daily dose, achieving a 65.9 percent PASI score reduction 15 days post-treatment. The drug demonstrated an elimination half-life of 6.5 days, with only mild adverse events reported.
The players
Ascletis Pharma
This is a Hong Kong-based biotechnology company focused on the discovery and development of treatments for liver and skin diseases.
The details
The trial used a randomized, double-blind, placebo-controlled design to evaluate the drug in the United States. Researchers observed no serious adverse events or hepatic safety signals throughout the treatment period.
Timeline
September 29, 2026: Ascletis announced the clinical trial results.
28 days: The total duration of the drug treatment phase.
6 days post-dose: PASI score reduction reached 60.7 percent.
15 days post-dose: PASI score reduction reached 65.9 percent.
Health Landscape
This clinical advancement follows a pattern set by the development of injectable antibody therapies for plaque psoriasis by offering a small-molecule oral alternative. It signifies a potential shift in treatment paradigms, potentially replacing complex injectable regimens with simplified oral dosing.
Patients may eventually see a shift from traditional injectable psoriasis treatments to more convenient, once-weekly oral pills. This transition could reduce the burden of treatment administration for individuals managing chronic plaque psoriasis.
The takeaway
The successful trial of ASC50 highlights the growing potential for oral small-molecule drugs to address conditions previously treated primarily with injections. Patients should consult with dermatologists to stay informed as these new treatment delivery methods move closer to clinical availability.
Further reading
For more information on dermatological conditions and clinical advancements, visit the Diseases — General section.
More information
For more information, visit the Ascletis corporate information portal.
Live Poll
Would you prefer an oral medication over injectable treatments if you had a chronic skin condition?
